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Resumo 
 
A presente tese tem como principal objectivo realçar a importância do trabalho 
desenvolvido num departamento de Qualidade de Producto & Compliance 
numa Indústria Farmacêutica no bom desempenho das actividades da 
empresa e no cumprimento dos seus objetivos e missão. Apesar da actividade 
deste departamento ser muito vasta o objectivo deste trabalho será cumprido 
através da descrição de algumas das tarefas executadas no âmbito deste. As 
tarefas descritas são, mais concretamente, as desempenhadas ao longo da 
minha experiência profissional na Bluepharma - Indústria Farmacêutica, S.A., 
iniciada em Junho de 2012 no departamento de Garantia da Qualidade, tendo 
continuidade até aos dias de hoje no agora designado departamento de 
Qualidade do Produto e Compliance.  
Esta dissertação está estruturada em 4 partes. No primeiro capítulo é feita 
uma introdução ao presente trabalho, com a sua contextualização e objetivos, 
seguindo-se uma breve abordagem do estado-da-arte da indústria 
farmacêutica, nomeadamente do contexto de mercado, do ambiente 
regulamentar e dos requisitos de qualidade. Neste capítulo é ainda 
apresentada a empresa e o departamento onde tem vindo a ser desenvolvida 
a minha atividade profissional. No capítulo seguinte são descritas as tarefas e 
atividades principais desempenhadas, as atividades complementares e as 
principais competências adquiridas ao longo desta experiência profissional. No 
final é apresentada uma discussão e conclusão, incluindo uma análise das 
atividades desenvolvidas, principais dificuldades sentidas, do papel e 
relevância das tarefas desenvolvidas no contexto global da empresa bem 
como das competências adquiridas durante esta experiência profissional. 
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abstract 
 
This thesis aims to highlight the importance of a Product Quality & Compliance 
department in a Pharmaceutical Industry, on the good performance of 
company's activities and the achievement of their goals and mission. Despite 
the wide activities performed by this Department, the purpose of this work will 
be completed by describing only some of their reponsibilities. The tasks 
described are specifically the ones I have been performing throughout my 
professional experience at Bluepharma - Pharmaceutical Industry, SA, initiated 
in June 2012 in the Quality Assurance Department until today in the currently 
named Product Quality & Compliance department. 
This thesis is structured into 4 parts. The first chapter is an introduction to this 
thesis, and includes its context and objectives, followed by a brief overview of 
the state-of-the art in the pharmaceutical industry, including the market 
environment, the regulatory environment and quality requirements. A small 
presentation of the company and the department where were and still are 
developed my professional activity is also made in this chapter. In the following 
chapter are described the main tasks performed, the complementary activities 
and key skills acquired throughout this professional experience. A discussion 
and conclusion is presented at the end, including an analysis of the reported 
activities, main difficulties encountered its role and importance in the company 
performance as well as the skills acquired during this work experience. 
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1. Introduction 
The present thesis elaborated under the scope of the Master’s Degree in Pharmaceutical 
Biomedicine will address the importance of a Product Quality & Compliance department in a 
Pharmaceutical Industry, on the good performance of company's activities and the achievement 
of their goals and mission by reflecting my working experience over the past two years up to the 
present at the Product Quality and Compliance Department (PQ&C), previously Quality 
Assurance Department, of Bluepharma Indústria - Farmacêutica, S.A., as well as to emphasize 
the learning outcomes acquired during this period. 
In order to better contextualize the theme proposed, this thesis will cover the current state of the 
art in the pharmaceutical industry focusing on pharmaceutical market, regulatory environment 
and quality demands. It will also be presented a brief vision of the institution as well as the 
positioning of the PQ&C department in the company, its interaction with other departments and 
main activities. 
Special emphasis will be given to the tasks that I have been performing in the framework of 
quality and the compliance and its relevance for the activities and mission of the company.  
Finally, a brief discussion will be presented concerning the different activities described in more 
detail within the Product Quality and Compliance, the main obstacles encountered in its 
execution, their contribution for the success of the company as well as the skills acquired during 
this work experiences. In the end a final keynote under the Conclusions section, highlight the 
most relevant messages and experiences. 
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1.1. Pharmaceutical Industry State-of-the-art 
This section intends to provide a brief overview of the current state of the art in pharmaceutical 
industry focusing on the pharmaceutical market, regulatory environment and Quality current 
demands in order to contextualize better the role of the assessment of product quality and 
compliance. Greater importance will be given to the European and North American context as 
these are the two main markets of the activities described in the development of this thesis. 
 
1.1.1. Pharmaceutical Market overview 
Article 1 of Directive 2001/83/EC as amended defines a 'medicinal product' as “Any substance 
or combination of substances presented as having properties for treating or preventing disease 
in human beings” and/or “Any substance or combination of substances which may be used in or 
administered to human beings either with a view to restoring, correcting or modifying 
physiological functions by exerting a pharmacological, immunological or metabolic action, or to 
making a medical diagnosis.” (1) 
Therefore, medicinal products have been over the years crucial in the improvement of health 
and/or quality of life and contributing largely to the world population life extension expectancy. 
According to the European Federation of Pharmaceutical Industries and Associations (EFPIA) 
report of 2012 European, citizens can expect to live up to 30 years longer than they did a 
century ago. (2) 
The pharmaceutical industry is responsible for the investigation, development, production and 
marketing of medicinal products, thus it represents an important sector in global economy.  
The total level of pharmaceutical revenue worldwide had reached is the latest years nearly one 
trillion United States (US) dollars being North America the responsible for the largest portion 
(more than 40%), mostly due to the leading role of the US pharmaceutical industry, followed by 
European and Japanese. (2) (3) Branded, patented medicines represent by far the largest share 
of pharmaceutical revenues. In 2012, Oncologics was the leading therapeutic class based on 
revenue (almost 62 billion US dollars of revenue globally) followed by other major therapy 
classes like pain drugs, antihypertensives and antidiabetics. (3) 
More than any other industry, the pharmaceutical sector is highly dependent on its research and 
development. Pharmaceutical companies invest 20 % more of their revenues in research and 
development (R&D) measures. (3) 
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All new medicines introduced into the market are the result of lengthy, costly and risky R&D 
conducted by pharmaceutical companies: it can takes 12-13 years from the first synthesis of the 
new active substance until the moment on which a medicinal product reaches the market; 
According to Mestre-Ferrandiz et al in 2012, cited in the European Federation of 
Pharmaceutical Industries and Associations’ (EFPIA) report of 2013, the cost of researching 
and developing a new chemical or biological entity was estimated at € 1,172 million ($ 1,506 
million dollars in 2011); finally, only one to two of every 10,000 substances synthesized in 
laboratories will successfully pass all stages of development required to become a marketable 
medicine. (4) 
As in other industries, in the pharmaceutical industry, the patent protects the extensive 
investment in research and clinical testing required before placing it on the market. This patent 
protection for pharmaceutical products is especially important compared with other industries 
once the actual manufacturing process is often easy to replicate and can be copied with a small 
fraction of the huge investment required for the research and clinical testing. Although, the time 
needed to obtain regulatory approval of these products (i.e. authorisation to put these products 
on the market) is in general very extensive and, therefore, the patent exclusivity period for 
pharmaceutical manufacturers is far shorter than in the case of other patent dependent 
industries and revenue losses due to patent expiry are often very significant. Thus, the 
development of new drugs is of vital importance for the pharmaceutical industry. (3) (5)  
In addition to the patents protection, to compensate for the inability to market inventions due to 
safety and efficacy regulation, both in Europe and in the US, it was addressed in legislation the 
possibility of a patent applicant apply for extensions of patent term. A supplementary protection 
certificate is a unique intellectual property (IP) right that extends the duration of the exclusive 
right. It enters into force after expiry of a patent upon which it is based. It comes into force only 
after the corresponding general patent expires. It normally has a maximum lifetime of 5 years 
and the total combined duration of market exclusivity of a general patent and supplementary 
protection certificate cannot normally exceed 15 years, barring exceptions (Article 36 of 
Regulation (EC) No 1901/2006)1. Although in the European Union (EU) all countries are 
required to provide supplementary protection certificates, no unified cross-recognition exist and 
therefore applications must be filed and approved on a country-by-country basis. (6)  
                                                     
1
 REGULATION (EC) No 1901/2006 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 12 December 2006 on medicinal 
products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation 
(EC) No 726/2004 that aims to facilitate the development and accessibility of medicinal products for use in the paediatric population, to 
ensure that medicinal products used to treat the paediatric population are subject to ethical research of high quality and are appropriately 
authorized for use in the paediatric population, and to improve the information available on the use of medicinal products in the various 
paediatric populations. 
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In Europe, besides the protection of innovation through patents and supplementary protection 
certificates, there are also specific “health laws” that govern generic medicinal products 
development and marketing. 
A generic medicine is a medicine that is developed to have similar Pharmacokinetic / 
Pharmacodynamic parameters as the reference medicine that has already been authorised, it 
contains the same active substance(s), is used at the same dose(s) to treat the same 
disease(s), however, the name of the medicine, its appearance (such as colour or shape) and 
its packaging can be different from those of the reference medicine. (7) 
Generics are usually produced by a manufacturer, who is not the inventor of the original 
product, and are marketed when intellectual property protection rights are expired. The market 
share of generics is significantly higher in new EU Member States with historically low levels of 
intellectual property protection while most of the new substances introduced in the market have 
their origin in the US. In 2009, the generic medicines market had an estimated value of €57 
billion in the top global markets. In Europe, European Generic Medicines Association estimated 
that generics medicines market size was of €31 billion in 2009. (4) (8) 
As for all medicines, generic medicines can only be marketed after having a marketing 
authorisation from a regulatory authority, such as the European Medicines Agency (EMA), 
granted after a scientific evaluation of the medicine’s efficacy, safety and quality. Consequently, 
the companies must submit quality, efficacy and safety data, including clinical data that proves 
the bioavailability and bioequivalence of the generic medicine vs. originator reference products 
to the regulatory authorities; all data provided to the competent authorities is assessed with the 
same accuracy than the innovator reference medicinal product already approved. Generic 
medicines are manufactured according to the same quality standards as all other medicines and 
its safety continues to be monitored after authorisation as well through the Pharmacovigilance 
system in place. (7) 
A company can only develop a generic medicine for marketing once the period of ‘exclusivity’ 
on the reference medicine has expired. This period of exclusivity is given by law to the company 
that developed the innovative medicine on which the generic medicine is based and comprises 
“data exclusivity” (typically 8 years from the date of first authorisation) after which valid 
applications for generic products can be submitted, and “market protection” after which generic 
products authorized in this way can be placed on the market (typically 10 years from the date of 
first authorisation). (7) (9) 
Contrary to what is the general perception that innovation is domain of the research-based 
originator companies, generic medicine companies spend a significant amount of their budgets 
on innovation. The generic medicine companies also invest on innovation to create new 
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strategies to overcome patents, for example, by improving formulations, enhancing delivery 
systems or by developing solutions to improve patient compliance. (7) (8). 
On average, 16.6% of total health expenditure in Europe is being spent on pharmaceuticals and 
other medical nondurables. Therefore the cost of drugs is a very important factor to have in 
account to maintain the sustainability of health systems. Economic and Financial Crisis in the 
EU reinforced the need for effective and efficient health care systems, as well as proper 
management of available resources. Consequently, generic medicines play an important role in 
health systems since they enable disease treatment at a lower cost, thus increasing the 
accessibility and availability of essential drugs to patients. (4) (8) 
Despite the advantages presented by generic medicines there is still some unfounded mistrust 
by health care professional and patients, arguing that they may be less safe, effective or that 
have less quality than the branded medicines  
 
 
1.1.2. Regulatory environment 
In order to protect public health, governments need to approve comprehensive laws and 
regulations and establish effective national regulatory authorities to ensure that the 
manufacture, trade, and use of medicines are regulated appropriately and that the public has 
access to accurate information on medicines. (10) 
 
European Legislation  
The European legislation related to medicinal products for human use comprises a set of legal 
instruments, that include legally bind acts (regulations, directives and decisions) and soft laws 
(Resolutions, Communications, Guidelines and notice to applicants). 
European pharmaceutical legislation is nowadays compiled in a set of publications globally 
named Eudralex that include 10 volumes. The body of European Union legislation in the 
pharmaceutical sector is compiled in Volume 1 and Volume 5 of the publication "The rules 
governing medicinal products in the European Union". 
 Volume 1 - EU pharmaceutical legislation for medicinal products for human use  
 Volume 5 - EU pharmaceutical legislation for medicinal products for veterinary use  
The basic legislation is supported by a series of guidelines that are also published in the 
following volumes of "The rules governing medicinal products in the European Union": 
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 Volume 2 - Notice to applicants and regulatory guidelines for medicinal products for 
human use  
 Volume 3 - Scientific guidelines for medicinal products for human use  
 Volume 4 - Guidelines for good manufacturing practices for medicinal products for 
human and veterinary use  
 Volume 6 - Notice to applicants and regulatory guidelines for medicinal products for 
veterinary use  
 Volume 7 - Scientific guidelines for medicinal products for veterinary use  
 Volume 8 - Maximum residue limits  
 Volume 9 - Guidelines for pharmacovigilance for medicinal products for human and 
veterinary use  
 Volume 10 - Guidelines for clinical trial  
Medicinal products for paediatric use, orphan, herbal medicinal products and advanced 
therapies are governed by specific rules. (11) 
 
 
Globalization trend 
Laws and regulations evolve within countries over time, but in recent years, the trend has been 
toward the globalization of pharmaceutical issues, which affects national legislation. This 
globalization, exemplified through changes in international trade, patent protection, and pricing, 
has resulted in a number of initiatives that must be considered by countries developing 
pharmaceutical regulations. International Conference on Harmonization (ICH) and 
Pharmacopoeias are some examples of these initiatives. (10) 
 
ICH 
Some of the biggest advances on regulations, established in order to assure the safeguarding 
of public health, were triggered by adverse incidents. Among these incidents, it stands out the 
tragedy with the thalidomide. In the late 1950s, thalidomide was approved in Europe and was 
prescribed to control sleep and nausea throughout pregnancy, but the American Authority 
(FDA) did not approve it in the US at the same time. Before getting approval in the US, it was 
found that taking this drug during pregnancy caused severe deformities in the foetus. (12) This 
tragic event emphasized the lack of proper policies, legislations and guidelines to ensure the 
safety, efficacy of a new drug and the absence of common criteria for the registration and 
marketing of pharmaceuticals, resultant from the different set of guidelines and laws used in 
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each country. Around the same time, the pharmaceutical industry started its internationalization 
process, seeking new global markets, becoming more evident these differences. The existing 
divergences in technical requirements from country to country, also lead to the duplication of 
test procedures, turning this global marketing process slow and expensive. (13)   
To optimize this process, harmonization of technical requirements was necessary. In 1990 it 
was launched International Conference on Harmonization (ICH) by drug regulatory authorities 
and pharmaceutical industrial members of Europe, Japan and US with the objective of providing 
guidelines to ensure the registration and marketing of safe, effective and high quality medicines.   
Representatives from six parties form ICH: Ministry of Health, Labour and Welfare (MHLW), and 
the Japan Pharmaceutical Manufacturers Association (JPMA) representing Japan, European 
Union (EU) and the European Federation of Pharmaceutical Industries and Associations 
(EFPIA) representing Europe, and Food and Drug Administration (FDA) and the Pharmaceutical 
Research and Manufacturers of America (PhRMA) representing the USA. Additional members 
include observers from the World Health Organization, European Free Trade Association and 
Canada. (14) 
The main purpose of ICH is to promote international harmonization in the interpretation and 
application of technical guidelines and requirements for pharmaceutical product registration. 
Consequently this process avoid duplication of clinical trials in humans, minimize the use of 
animal testing without compromising safety and effectiveness, streamline the regulatory 
assessment process for new drug applications and reduce the development times and 
resources for drug development. (15) This way, it turns possible to develop safe, effective, and 
high quality medicines, at a lower cost and with a minimum of delay in make it available to 
patients. The Harmonization is achieve through the development of ICH Tripartite Guidelines. 
ICH Guidelines are divided into four categories:  
- Quality Guidelines: include pivotal milestones such as the conduct of stability studies, 
definition of relevant thresholds for impurities testing and a more flexible approach to 
pharmaceutical quality based on Good Manufacturing Practice (GMP) risk management. 
- Safety Guidelines: to uncover potential risks like carcinogenicity, genotoxicity and 
reprotoxicity.  
- Efficacy Guidelines:  embraces the design, conduct, safety and reporting of clinical trials 
(Good Clinical Practices). It also covers novel types of medicines derived from biotechnological 
processes and pharmacogenetics/genomics techniques. 
- Multidisciplinary Guidelines: other topics which do not fit uniquely into one of the previous 
topics like the ICH medical terminology (MedDRA), the Common Technical Document (CTD) 
and the development of Electronic Standards for the Transfer of Regulatory Information. (16) 
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One of the most important achievements of the ICH was the creation of the Common Technical 
Document (CTD), through an Industry proposal in 1996. The CTD, and since 2006 the 
electronic CTD (eCTD) had revolutionised the submission process, by easing the process both 
for pharmaceutical companies and for regulatory authorities, by allowing for example the 
submission of a single technical dossier in the three ICH regions instead of a multiple complex 
submissions, therefore saving time and resources. (17) 
The Common Technical Document is organized into five modules containing non-clinical, 
clinical and quality information (Figure 1):  
1. Administrative and prescribing information; 
2. Overview and summary of modules 3 to 5; 
3. Quality (pharmaceutical documentation); 
4. Preclinical (Pharmacology/Toxicology); 
5. Clinical – efficacy (Clinical Trials). 
 
 
Figure 1- Diagrammatic Representation of the Organization of the CTD (17) 
 
Module 1 contains the regional and administrative information and it is specific for each region. 
The other four modules are common to the three regions and are in a harmonised format. (17) 
The Quality section of the Common Technical Document (Module 3) provides a harmonised 
structure and format for presenting Chemistry, Manufacturing and Controls information in a 
registration dossier. The table of contents includes sections on Drug Substance (DS) and Drug 
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Product (DP). There are also sections for regional specific information as well as some 
appendices. (17) 
The content of the dossier differ with the medicine product aimed (complete, generic medicinal 
products and similar biological products; well-established medicinal bibliographic; new fixed 
combination products). (18)  
A CTD for a generic product contains Modules 1, 2, 3 and 5. Module 4 does not need to be 
included in a CTD for a generic drug, since all relevant non-clinical information for the active 
substance of the drug product is already documented. There are also some significant 
differences in a generic CTD content, towards a reference medicine CTD, concerning the 
European context: Module 1 of a CTD for a generic Marketing Authorisation Application, has to 
include a summary of the grounds and evidence, used for demonstrating that the medicinal 
product for which an application is submitted is a generic of a reference therapeutic product 
(qualitative and quantitative composition in active substance, pharmaceutical form, 
bioequivalence information and its safety and efficacy profile in comparison to the reference 
medicinal product); Module 2 of a CTD for a generic drug must include the Quality Overall 
Summary but differently from a normal CTD the summaries of the non-clinical and clinical 
studies are only mandatory if new studies have been conducted for the generic drug; Module 3 
of a generic drug has to be filled and presented according to what is described in ICH M4Q and 
WHO’s “Guideline on submission of documentation for a multisource (generic) ﬁnished 
pharmaceutical product (FPP) quality part”; Module 5 is included once most generic drug 
products market applications are supported by one or more pivotal comparative bioavailability 
studies, performed in order to assess their bioequivalence to the original drug product, however, 
since no other clinical studies are required for generic drug products, this module is much 
shorter than the one for an original drug product. (19) 
For the purpose of this thesis, some sections of Module 3 will be further detailed. 
In the US, an Abbreviated New Drug Application (ANDA) is submitted to the FDA when seeking 
review and approval for a generic drug product. The ANDA is submitted to FDA's Center for 
Drug Evaluation and Research, Office of Generic Drugs and contains essential data for the 
review and ultimate approval of a generic drug product. Once approved, an applicant may 
manufacture and market the generic drug for the American market. 
 
Pharmacopoeias 
Pharmacopoeias are documents that outline technical information, manufacturing and testing 
procedures, and standards for active pharmaceutical substances and products.  
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A pharmacopoeia is usually recognized as part of a country’s national pharmaceutical laws, 
therefore, the standards and procedures are legally enforceable. Because of the extensive 
resources required to produce and maintain these complex documents, most countries do not 
have national pharmacopoeias and rely on one or more internationally recognized 
pharmacopoeias, such as those from the United States (USP/NF), the European Pharmacopeia 
(Ph.Eur.) from the European Union, Japan, or World Health Organization. The organizations 
that publish pharmacopoeias, pressured by the need to facilitate international trade, are actively 
working to harmonize their requirements. 
 
 
Marketing authorisation procedures in the European Union 
Directive 2001/83 /EC, also known as the Consolidated Directive, govern the regulation of 
medicinal products in the EU. This legislation brings up in one document legislation and 
regulatory issues concerning medicine products including rules concerning specific categories 
of medicines, manufacture, importation and distribution, labelling and advertising, the 
classification of medicinal products, and pharmacovigilance. This Directive has been 
implemented into the national laws of each EU member state and adopted by other members of 
the European Economic Area (EEA): Norway, Iceland, and Liechtenstein (the Swiss system 
also mirrors EU regulation). In all its complexity, this directive states one fundamental premise: 
“No medicinal product may be placed on the market in the EU unless the relevant competent 
authority grants a marketing authorisation.” (18) 
The “Notice to applicants: VOLUME 2A - Procedures for marketing authorisation”, prepared by 
European Commission in consultation with competent authorities of the Member States and 
EMA, in order to facilitate the interpretation and application of the European Legislation, also 
states: “A medicinal product may only be placed on the market in the European Economic Area 
(EEA) when a marketing authorisation has been issued by the competent authority of a Member 
State (or EEA country) for its own territory (national authorisation) or when an authorisation has 
been granted in accordance with Regulation (EC) No 726/2004 for the entire Community (a 
Community authorisation). The marketing authorisation holder must be established within the 
EEA.” (20) 
In order to obtain a marketing authorisation (MA) the applicants should submit a full dossier to 
competent authority that details, among other things, product’s common or scientific name, 
invented name, qualitative and quantitative particulars, proposed therapeutic indications, 
contraindications, and adverse reactions, as well as the results of pharmaceutical and 
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preclinical tests and clinical trials. This dossier must be prepared in the EU CTD format, 
previously described, according to the medicine product aimed. 
Marketing authorisations are valid for an initial period of five years, after which they may be 
renewed. Once approved, the holder is under an obligation to continually update the 
authorisation in order to ensure compliance with scientific progress and new regulatory 
requirements and especially to assure a constant evaluation of the benefits and risks of the 
product. (21) 
There are four different procedures to obtain a Marketing Authorisation (MA): 
 Centralised Procedure: this procedure allows the introduction of the medicinal product 
in all the countries in EEA, (EU Member States and also Iceland, Liechtenstein 
Norway). The application is made directly to the EMA.. (21) (20) 
 Mutual Recognition Procedure: this procedure applies when a medicinal product has 
already a MA in one Reference Member State and the applicant wants to obtain a MA in 
another member state or, at the time of submission, the same medicinal product is 
being assessed by more than one Member States. (21) (20) 
 Decentralised Procedure: this procedure is an alternative to mutual recognition 
procedure used to obtain marketing authorisations in several Member States, when the 
medicinal product in question has not received previously a marketing authorisation in 
any MS, at the time of application. (21) (18) 
 National Procedure: In this procedure, the regulatory authority of each member state 
country is responsible for granting marketing authorisation for its own country. (21) (18) 
 
 
Regulatory Bodies 
The life cycle of any drug involves several phases. The initial phases of basic research, disease 
discovery and drug discovery are not regulated but the following Preclinical Development, 
Clinical Trials (I, II and III), Manufacturing (including Drug Substances) and Market Launch, are 
(2).  
Several Regulatory Agencies exist in most territories to oversee the development, approval, and 
marketing of drugs as well as their behaviour during the lifecycle. 
 
European Medicines Agency (EMA) 
The European Medicines Agency (EMA) is the European Union body responsible for the 
protection and promotion of public and animal health, through the evaluation and supervision of 
medicines for human and veterinary use. EMA cooperates with the existent Member States in 
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the evaluation, supervision and pharmacovigilance of medicinal products. The main activities of 
EMA are related with marketing authorisations; safety monitoring of medicines and inspections. 
(22) 
 
 
European Directorate for the Quality of Medicines and Healthcare (EDQM) 
EDQM is another important EU Regulatory body of the European Medicines Regulatory 
System. It co-ordinates several activities in 47 countries including the responsibility for the 
European Pharmacopoeia, co-ordination of other medicines control activities via national 
agencies, inspectorates etc., and the emission of the Certificates of Suitability of Drug 
substances after inspection to manufacturers facilities. (23) 
 
National Competent Authorities 
National Competent Authorities are Medicines Agencies responsible for regulate/ supervise the 
medicinal products sector at a National Level. They have also responsibilities on Marketing 
Authorisations (for each Member State in the Mutual Recognition, Decentralized or National 
Procedure), Safety monitoring (monitor and assurance of national medicines vigilance systems) 
and Inspections (assurance of compliance with good practices (GXP)). (21) 
INFARMED is the Portuguese National Authority of Medicines and Health Products, IP, is a 
Government agency accountable to the Health Ministry created to monitor, assess and regulate 
all activities relating to human medicines and health products for the protection of Public Health. 
 
Food and Drug Administration (FDA) 
FDA is the United States of America agency responsible for “protecting the public health by 
assuring the safety, efficacy and security of human and veterinary drugs, biological products, 
medical devices, our nation’s food supply, cosmetics, and products that emit radiation (5).” 
Concerning medicines FDA has in the US similar responsibilities to EMA on marketing 
authorisations, safety monitoring of medicines and inspections. The FDA inspections cover also 
several areas: Current GMP Inspections, Clinical Investigator Inspections, GLP Inspections and 
Pharmacovigilance Inspections. (24) 
 
Pharmaceutical Inspection Convention” and the “Pharmaceutical Inspection Co-operation 
Scheme” (PIC/S) 
In order to provide a joint active and constructive co-operation in the field of GMP between 
countries and pharmaceutical inspection authorities, was also created the “Pharmaceutical 
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Inspection Convention” and the “Pharmaceutical Inspection Co-operation Scheme” (jointly 
referred to as PIC/S). PIC/S' mission is "to lead the international development, implementation 
and maintenance of harmonised GMP standards and quality systems of inspectorates in the 
field of medicinal products”. For that they develop and promote harmonised GMP standards and 
guidance documents, provide training to competent authorities, in particular inspectors, assess 
(and reassess) inspectorates and encourages the co-operation between competent authorities 
and international organizations. (25) 
 
From the several activities performed by the regulatory authorities, stand out three main focus:  
- Product development – pre-authorisation phase 
The regulatory authorities will grant a MA after evaluating all the data provided in the CTD to 
demonstrate the efficacy, safety and quality of the product and if all that information is 
satisfactory. The approved MA is valid for 5 years and should be renewed at the end of that 
period. After having an approved MA, the product shall be placed on the market within a period 
of three years (“sunset clause”). (26) 
- Product manufacture 
The manufacturing or importation of medicinal products, including investigational medicinal 
products, is subject to a manufacturing or import authorisation. The holder of such authorisation 
is obliged to comply with the principles and guidelines of Good Manufacturing Practice (GMPs) 
for medicinal or experimental products and to use as starting materials only drug substances 
(active pharmaceutical ingredients), which have been manufactured in accordance with GMP 
Part II. (Title IV of Directive 2001/83/EC); Article 13 of Directive 2001/20/EC, Title IV of Directive 
2001/82/EC ). GMP´s are a set of norms and procedures of legal framework that govern the 
pharmaceutical industry activity. The GMP include the basic requirements for medicinal 
products (Part I), basic requirements for active substances used as starting materials (Part II), 
GMP related documents (Part III) and Annexes. GMP aim to ensure that medicinal products are 
consistently produced and controlled to the quality standards appropriate to their intended use 
and as required by the marketing authorisation (MA) or product specification. GMP is a part of 
quality assurance that concerns both production and quality control; it defines general measures 
to ensure that processes necessary for production and testing are clearly defined, validated, 
reviewed and documented, and that the personnel, premises and materials are suitable for the 
production of the intended medicinal products. GMP also covers distribution, contract 
manufacturing and testing, and responses to product defects and complaints. All medicinal 
products manufacturers for human use have the obligation to possess a GMP Certificate issued 
by EU National CA after verification and inspection of the activities and procedures 
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implemented in the pharmaceutical facilities/sites. Manufacturing sites must follow the principles 
and guidelines of the GMP assuring that the production of medicinal products is performed and 
controlled according to quality standards. In order to verify the compliance with GMP principles 
and relevant regulatory requirements, National CA perform regular inspections to the sites. (1) 
(27) 
Additionally, since the wholesale distribution of medicinal products is also an important activity 
in the integrated supply chain management and the quality and the integrity of medicinal 
products can be affected by a lack of adequate control, the European Commission has also 
published guidelines on Good Distribution Practice (GDP) of medicinal products for human use. 
(28) 
- Pharmacovigilance 
According to World Health Organisation, “Pharmacovigilance is the science and activities 
relating to the detection, assessment, understanding and prevention of adverse effects or any 
other medicine-related problem”. (29) When is granted a MA to a medicinal product, it does not 
mean that it does not have any safety issue. It means that, based on the current scientific 
knowledge, the benefits outweigh identified risks. At that time, the information concerning the 
safety and efficacy information of the medicinal product is limited, since the information is based 
on a reduced number of patients that were studied only under the controlled conditions of 
randomised clinical trials. There is no long-term treatment data available, the inclusion criteria 
are narrow, higher risk subgroups are not included in clinical trials as well as patients with 
concomitant illnesses that require use of other medicinal products. These factors determine the 
need for continuing to analyse and assess relevant safety and effectiveness information 
throughout the medicinal product’s lifecycle (21) (30). Regulatory authorities have implemented 
systems for a systematic collection and assessment of information about adverse drug 
reactions, over the product’s lifetime. These systems allow identifying risks that did not emerge 
during the pre-marketing phase and that only could be identified in real life conditions. (30) 
 
 
1.1.3. Quality on Pharmaceutical Development and 
Manufacturing 
As it was referred before medicinal products must be developed/produced in accordance with 
the principles and the detailed guidelines of Good Manufacturing Practice for Medicinal 
Products detailed on Volume 4 of Eudralex. This Volume comprises an introduction, three parts 
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and is supplemented by a series of annexes. The introduction includes the Directives 
2003/94/EC and 91/412/EC were are laid down the principles of GMP, Part I covers GMP 
principles for the manufacture of medicinal products, part II covers GMP for active substances 
used as starting materials, part III contains GMP related documents, which clarify regulatory 
expectations and Annexes include guidance on several issues like Sampling of Starting and 
Packaging Materials (Annex 8), Computerised Systems (Annex 11), Manufacture of 
Investigational Medicinal Products (Annex 13), Qualification and validation Annex 15, 
Certification by a Qualified person and Batch Release (Annex 16), Reference and Retention 
Samples (Annex 19), among others.  
Part III is intended to host a collection of GMP related documents, which are not detailed 
guidelines on the principles of GMP laid down in Directives 2003/94/EC and 91/412/EC. (28) 
Among the documents included in Part III are two of the ICH guidelines that have arisen in the 
Quality area: 
 ICH Q9 - Quality Risk Management 
 ICH Q10 - Pharmaceutical Quality Systems 
However, other quality guidelines should be taken into account depending on the type of 
product and on the stage of development or phase of manufacturing: 
 Q1A - Q1F Stability  
 Q2 Analytical Validation  
 Q3A - Q3D Impurities  
 Q4 - Q4B Pharmacopoeias  
 Q5A - Q5E Quality of Biotechnological Products  
 Q6A- Q6B Specifications  
 Q7 Good Manufacturing Practice  
 Q8 Pharmaceutical Development 
 Q11 Development and Manufacture of Drug Substances  
 Q12 Lifecycle Management. 
These guidelines are a harmonised global quality standards and interpretation based on good 
science and risk management principles. These guidelines have been developed by ICH Expert 
Working Group and have been subject to consultation by regulatory entities including FDA and 
EMA that, therefore recommend its use. (16) 
ICH Q8, Q9 and Q10 guidelines encourages systematic and science and risk-based 
approaches that are intended to work together to enhance pharmaceutical product quality. 
These guidelines are applicable over the entire product lifecycle and therefore, will be further 
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detailed in this section to better understand the demands and trends for quality in 
pharmaceutical industry. 
Other guidelines, focused on essential milestones, such as, the conduct of stability studies 
(Q1A – Q1F), the definition of relevant thresholds for impurities testing (Q3A – Q3D), the 
definition of criteria on how to set specifications for drug substances (Q4 – Q4B) or on how to 
select tests, methods and set specifications for the testing of drug substances and dosage 
forms (Q6A – Q6B), will be opportunely mentioned throughout this thesis. 
 
ICH Q8 
The aim of pharmaceutical development is to design a quality product and its manufacturing 
process to consistently deliver the intended performance of the product. The ICH Common 
Technical Document (CTD) includes a section concerning Pharmaceutical Development 
(3.2.P.2). This section is intended to provide a comprehensive understanding of the product and 
manufacturing process for reviewers and inspectors. It is first produced for the original 
marketing application and can be updated to support new knowledge gained over the lifecycle 
of a product.  
ICH Q8 guideline describes the suggested contents for the 3.2.P.2 (Pharmaceutical 
Development) section and also indicates areas where the demonstration of greater 
understanding of pharmaceutical and manufacturing sciences can create a basis for flexible 
regulatory approaches. It also includes further clarification of key concepts and tools outlined in 
the core Guideline, like “quality by design” 2 and “design space”3, through which can be created 
a basis for more flexible regulatory approaches. (31) 
Is the information and knowledge gained from pharmaceutical development studies and 
manufacturing experience that provide scientific understanding to support the establishment of 
the “design space”, specifications, and manufacturing controls.  
 
 
ICH Q9 
The manufacturing and use of a medicinal product, including its components, necessarily entail 
some degree of risk. The risk to its quality is just one component of the overall risk. It is 
important to understand that product quality should be maintained throughout the product 
lifecycle, such that, the attributes that are important to the quality of the medicinal product 
                                                     
2
 Quality by Design is defined in the ICH Q8 as “a systematic approach to development that begins with predefined objectives and 
emphasizes product and process understanding and process control, based on sound science and quality risk management”.  
 
3 Design space is defined in the ICH Q8 as the multidimensional combination and interaction of input variables (e.g., material attributes) 
and process parameters, that have been demonstrated to provide assurance of quality.  
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remain consistent with those used in the clinical studies. An effective quality risk management 
approach can further ensure the high quality of the medicinal product to the patient by providing 
a proactive means to identify and control potential quality issues during development and 
manufacturing. Additionally, use of quality risk management can improve the decision making if 
a quality problem arises. Effective quality risk management can facilitate better and more 
informed decisions, can provide regulators with greater assurance of a company’s ability to deal 
with potential risks and can beneficially affect the extent and level of direct regulatory oversight. 
(32) 
Quality risk management is a systematic process for the assessment, control, communication 
and review of risks to the quality of the medicinal product across the product lifecycle. It is 
integral to an effective pharmaceutical quality system and facilitates continual improvement of 
process performance and product quality throughout the product lifecycle. (33) 
The two primary principles of quality risk management are: 
- the evaluation of the risk to quality should be based on scientific knowledge and 
ultimately link to the protection of the patient; and  
- the level of effort, formality and documentation of the quality risk management process 
should be commensurate with the level of risk. (32) 
ICH Q9 provides principles and examples of tools for quality risk management that can be 
applied to different aspects of pharmaceutical quality. It can be applied not only in the 
manufacturing environment, but also in connection with pharmaceutical development and 
preparation of the quality part of marketing authorisation dossiers. The guideline applies also to 
the regulatory authorities in the fields of pharmaceutical assessment of the quality part of the 
marketing authorisation dossier, GMP inspections and the handling of suspected quality 
defects. (32) 
Quality risk management should be integrated into existing operations and documented 
appropriately. In the pharmaceutical area, the use of the quality risk management process might 
provide information that could then be used in a variety of pharmaceutical operations in several 
situations: 
- industry and regulatory operations: quality management; 
- industry operations and activities: development, facilities, equipment and utilities, 
materials management, production, laboratory control and stability testing, packaging 
and labelling; 
- regulatory operations: inspection and assessment activities. (32) 
While regulatory decisions will continue to be taken on a regional basis, a common 
understanding and application of quality risk management principles could facilitate mutual 
confidence and promote more consistent decisions among regulators on the basis of the same 
information. (32) 
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ICH Q10  
ICH Q10 establishes a model for an effective quality management system for pharmaceutical 
industry throughout the lifecycle of a product, referred to as the Pharmaceutical Quality System, 
by describing specific quality system elements and management responsibilities. (e.g., 
Development).  
This model is based on International Standards Organisation (ISO) quality concepts, includes 
applicable Good Manufacturing Practice (GMP) regulations and complements ICH Q8 
“Pharmaceutical Development” and ICH Q9 “Quality Risk Management”. ICH Q10 is intended to 
be used together with regional GMP requirements but has a wider application since the regional 
GMPs do not explicitly address all stages of the product lifecycle. ICH Q10 can be implemented 
throughout: 
- Pharmaceutical Development: drug substance development; formulation development 
(including container/closure system); manufacture of investigational products; delivery 
system development (where relevant); manufacturing process development and scale-
up; analytical method development. 
- Technology transfer: new product transfers during development through 
manufacturing; transfers within or between manufacturing and testing sites for 
marketed products. 
- Commercial manufacturing: acquisition and control of materials; provision of facilities, 
utilities, and equipment; production (including packaging and labelling); quality control 
and assurance; release; storage; distribution (excluding wholesaler activities). 
- Product discontinuation: retention of documentation; sample retention; continued 
product assessment and reporting. (33) 
This guideline applies to the systems supporting the development and manufacture of 
pharmaceutical drug substances and drug products, throughout the product lifecycle and its 
application should facilitate innovation and continual improvement and strengthen the link 
between pharmaceutical development and manufacturing activities. (33) 
Implementation of the Q10 model should result in achievement of three main objectives which 
complement or enhance regional GMP requirements: 
- Achieve product realization: by establishing, implementing and maintaining a system 
that allows the delivery of products with the quality attributes appropriate to meet the 
needs of patients, health care professionals, regulatory authorities (including 
compliance with approved regulatory filings) and other internal and external customers. 
- Establish and maintain a state of control: by developing and using effective monitoring 
and control systems for process performance and product quality, thereby providing 
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assurance of continued suitability and capability of processes. Quality risk 
management can be useful in identifying the monitoring and control systems.  
- Facilitate continual improvement: by identifying and implementing appropriate product 
quality improvements, process improvements, variability reduction, innovations and 
pharmaceutical quality system enhancements, thereby increasing the ability to fulfil 
quality needs consistently.  
Throughout the product lifecycle, companies are encouraged to evaluate opportunities for 
innovative approaches to improve product quality. There are four Pharmaceutical quality system 
elements required under regional GMP regulations that are enhanced by ICH Q10 in order to 
promote the lifecycle approach to product quality. These four elements are: 
- Process performance and product quality monitoring system: by establishing 
parameters and attributes (e.g. related to drug substance and drug product materials 
and components, facilities and equipment operating conditions, in-process controls, 
finished product specifications, and the associated methods), a frequency of monitoring 
and control and using the appropriate tools is easier to identify sources of variation that 
affect process performance and product quality and therefore enables the 
implementation of continual improvement activities to reduce or control variation; 
- Corrective action and preventive action (CAPA) system: the pharmaceutical company 
should have a system for implementing corrective actions and preventive actions 
resulting from the investigation of complaints, product rejections, non-conformances, 
recalls, deviations, audits, regulatory inspections and findings, and trends from process 
performance and product quality monitoring. 
- Change management system: innovation, continual improvement, the outputs of 
process performance and product quality monitoring and CAPA impels changes that 
should be properly evaluated. This evaluation must be performed by expert teams with 
representatives from relevant areas (e.g., Pharmaceutical Development, 
Manufacturing, Quality, Regulatory Affairs and Medical) and should be done, not only 
to ensure that those changes are technically justified, but also to evaluate, after 
implementation, if the objectives of the change were achieved and if there was no 
deleterious impact on product quality. 
- Management review of process performance and product quality: it should be provided 
assurance that process performance and product quality are managed over the 
lifecycle. Depending on the size and complexity of the company, management review 
can comprise a series of reviews at various levels of management and should include 
a timely and effective communication and escalation process. The management review 
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system should include: results of regulatory inspections and findings, audits, other 
assessments and commitments made to regulatory authorities, or periodic quality 
reviews concerning customer satisfaction (complaints), conclusions of process 
performance and product quality monitoring, effectiveness of process and product 
changes (including those arising from corrective action and preventive actions) and any 
follow-up actions from previous management reviews. Through an effective 
management review system should be identified appropriate actions, such as 
improvements to manufacturing processes and products; provision, training and/or 
realignment of resources; capture and dissemination of knowledge. (33) 
Nowadays Pharmaceutical Industries comprise all the four stages of product lifecycle referred to 
in the ICH Q10, including the development stage. Focusing on the remaining stages, we can 
conclude that that are several advantages on implementing a robust Pharmaceutical Quality 
System. 
- Improve manufacturing processes thus reducing undesired variability and leading to a 
more consistent product quality, improved process robustness and more efficiency; 
- Decrease the incidence of complaints, recalls and risk of product failure; 
- Take actions before a problem and avoid future failure  following  continuous 
improvement changes; 
-  Quality assurance along the throughout life cycle of the drugs providing a continuous 
improvement of the processes; 
- Increase compliance with GMPs; 
- Demonstrate an effective quality system to regulatory authorities especially during the 
inspections; 
- Greater confidence in product quality by all stakeholders (manufacturers, regulators and 
patients); 
- Cost reduction by decreasing waste, processes duplication and reworks. (33) (34) 
 
The implementation of Q8, 9 &10 is valuable for all drug products, development approaches 
and regulatory systems and is essential to achieve ICH Quality Vision. These Guidelines can be 
used both by Industry and by regulators (e.g., assessors and inspectors are expected to 
incorporate QRM during regulatory processes). 
Good scientific development (Q8) in combination with Quality Risk Management (Q9) and 
Pharmaceutical Quality System (Q10) will improve drug quality and efficiency of pharmaceutical 
manufacturing.   
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1.2. Overview of the Company 
Bluepharma is a privately owned Portuguese pharmaceutical company based in Coimbra. It 
was founded in February 2001, by a group of Portuguese professionals connected with the 
pharmaceutical industry who acquired Bayer’s industrial unit, taking advantage not only of the 
facilities and equipment but also of the human resources with more than 30 years of 
experience. Throughout the years, Bluepharma has successfully reshaped its business model 
and went from being a traditional contract manufacturing organization to a company that 
promotes innovation, registers, licenses and exports its product internationally. Through the 
companies of the group, Bluepharma offers an integrated approach on the process of drug 
discovery and drug development, including innovative research of New Chemical Entities (NCE) 
and New Therapeutic Entities (NTE - based on novel platforms for the delivery of known drugs) 
as well as the development, manufacturing and commercialization of solid dosage forms. Its 
main activities thus include: 
a) Research & Development 
- Dedicated facilities with highly qualified scientists focused on the development of solid 
dosage forms, including pre-formulation and formulation studies, development of 
analytical methods, scale up, ICH stability and compilation of CMC. 
- Development of novel and versatile oral strip formulations aiming at providing solutions 
for unmet medical needs. 
- Research and development of innovative photosensitizer compounds to be used in 
Photodynamic Therapy (PDT) or Photodiagnosis (PDx) of cancer or other diseases; 
One of the lead compounds – LUZ11 – is currently in phase IIa clinical trials in head and 
neck advanced cancer. 
- Research and development of innovative targeted nanoparticles (PEGASEMP) capable 
of targeting two distinct cell populations in the tumour: the cancer cell and the blood 
vessels that nurture the tumour.  PEGASEMP has entered the formal non-clinical 
program in 2013. 
- Clinical pharmacology unit devoted to perform phase 1 clinical trials in healthy 
volunteers and selected populations of patients. 
 
b) Industrial activities 
- State-of-the-art manufacturing site for solid dosage forms; approved by US, Korean, 
Taiwan, Iran and EU authorities; capacities for 2.0 Billion units (tablets and capsules). 
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c) Commercialization of medicines 
- Large portfolio of products covering the main therapeutic areas reflecting in export 
activities worldwide. 
 
This integrated approach has allowed Bluepharma to offer solutions covering every stage of the 
drug development process and was achieved by investing over 20 million euros since 2001 in 
extensive improvements, making it the Portuguese pharmaceutical SME that invests more in 
Research, Development and Innovation activities.   
 
Bluepharma’s mission is to offer pharmaceutical products of the highest quality at competitive 
prices, contributing to the rationalization of expenses in the health sector and simultaneously to 
the improvement of the life quality of populations. (35) (36) This commitment towards quality 
and lean management has been paramount to the firm’s activities, and is achieved through the 
implementation of a Quality, Environment, Health and Safety System, supported by ISO Norms 
9001, ISO 14001 and OHSAS 18001, by the Good Manufacturing Practices and by other 
applicable legislation. 
Bluepharma is a GMP certificated company by INFARMED, I.P .(Portuguese National Authority 
of Medicines and Health Products) and is authorised to manufacture different non-sterile 
products in the following solid dosage forms: capsules, hard shell, tablets, powder and granules. 
In 2003, became the first pharmaceutical company in Portugal that accumulates combined 
certifications in quality (ISO 9001/2000), environment (ISO 14001/1999), safety and 
occupational health (OHSAS 18000). In 2009 obtains official approval by the US Authority 
(FDA) for the development / manufacture of solid pharmaceutical forms, becoming the first 
Portuguese pharmaceutical company to export to the American market. Bluepharma has also 
certification in RDI - Research, Development and Innovation by the Portuguese Authoritie 
APCER (NP 4457) (36) 
 
Looking ahead, Bluepharma is currently investing in emerging fields such as oncology, 
nanotechnology and biotechnology, by establishing partnerships with the most prominent local 
and international research centres and multinational pharmaceutical companies. (36) 
The structure of the company and the relationships and relative ranks of its parts is represented 
in figure 2. 
The Product Quality and Compliance is under the coordination of the Vice President Head of 
Operations/ Head of QASOS and its activity is interrelated with all sectors of the company. 
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1.3. Product Quality and Compliance Department 
Until the end of 2012 Quality Assurance Department of Bluepharma was responsible for the 
Integrated Management including all the quality system in place in the company and also 
environmental, occupational health and safety systems. 
In January 2013 the department Quality Assurance Department has undergone a restructuring 
process. In practical terms, a new department for product quality and compliance was created, to 
address all quality matters inherent to the production (from the raw materials until the release of 
finished product, including equipment and infrastructures product related), product compliance and 
release of pharmaceutical products (human, veterinary and experimental medicines). 
The PQ&C assumed the following main responsibilities and tasks: 
- Management of change control and Risk Management related to the materials/ products/ 
processes/ equipment/ infrastructures/ Information and technology (IT); 
- Management of manufacturing and packaging deviation reports, equipment and 
infrastructures DR, Out-of-specifications, Out-of-trend, Corrective actions, preventive 
actions and technical complaints; 
- Validation, Qualification and Calibrations, of all the GMP relevant equipment, support 
systems, information technologies systems, infrastructure and related processes; 
- Cleaning Validation 
- Research & Development support (preparation of all documentation of pilot batches as  
manufacturing, packaging and process validation) and release to chemical trials; 
- SAP Computer System (preparation and revise of SAP inspection plans for raw-materials, 
packaging materials, bulk product and finished product);  
- Product Documentation (Preparation. Verification and Approval of manufacturing, 
packaging and quality control documentation); 
- Assessment of Product Compliance (manufacturing, packaging, quality control and 
validation documentation); 
- Product Quality Reviews (PQRs); 
- Technical Supervision of Manufacturing and Packaging processes (in loco  and of all the 
related documents) 
- Training; 
- Audits and respective CAPA follow up. 
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The Head of Product Quality & Compliance is also the Qualified Person (QP) of the Company for 
the experimental medicines, human and veterinary medicines, and therefore the preparation/ 
review/ approval/ archive of Quality Agreements, the release of the product for the market and for 
clinical trials, the management of all pharmaceutical acts performed during manufacturing / 
packaging and analysis are some of other responsibilities that fall within the scope of this 
department and its staff.  
Considering all the responsibilities and tasks described above it is clear that the work undertaken in 
this department is transversal to the entire company and is fundamental to its operation and to 
ensure compliance with quality commitment. 
Within the scope of this thesis, only some of the tasks listed before will be detailed.  
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2. On-the-job activities 
This chapter intends to describe all the activities, tasks developed, and learning outcomes acquired 
throughout my professional experience at Bluepharma. 
This chapter is organised in three sections: 
 Main activities performed 
 Additional activities performed 
 On-the job additional learning. 
 
 
2.1. 2.1. Main Activities 
My career in Bluepharma began in June 2012 in the Department of Quality Assurance. After a 
period of integration in the department and specific training, the preparation of Product Quality 
Reviews (PQRs) was assigned to me as my main task. Lately with the division of the department, I 
was allocated to the Product Quality and Compliance department and there was a readjustment of 
my responsibilities and tasks. While retaining the responsibility for conducting PQRs I was also 
given the responsibility of preparing/ reviewing analytical documentation (specifications, analytical 
procedures) and perform other related tasks, as the verification of Compliance with the 
requirements of the Marketing Authorisation Dossier (MAD) or the Abbreviated New Drug 
Application/ New Drug Application (ANDA / NDA). 
 
 
2.1.1. Product Quality Reviews 
 
Overall requirements 
Product Quality Review is a GMP requirement listed under Chapter 1 of the PIC/S GMP Guide for 
Medicinal Products, effective since 1 Jan 2006. (37) (38) 
In the European Union this guide has been adopted by the Ad hoc GMP inspectors Working Group 
at their first meeting in July 2003. The proposal of Product Quality Review arises from the 
experience of Member States’ inspectorates where quality problems with products on the market 
leading to recall could have been anticipated if the manufacturer/marketing authorisation holder 
had operated a system for formally reviewing process consistency and trends. FDA also dictated in 
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their 21 Code of Federal Regulation (CFR) – Parts 210 & 211 the requirements of reviewing the 
products annually where clearly states that written records, required by the part, shall be 
maintained so that data can be used for evaluating, at least annually, the quality standards of each 
drug product to determine the need for changes in drug product specifications or manufacturing or 
control procedures. Also the ICH in the ICH Q7A GMP Guide for Active Pharmaceutical Ingredients 
requires manufacturers to conduct annual quality review of the active pharmaceutical ingredients in 
order to know the consistency on the quality of products manufactured throughout the year. (37) 
Essentially, product quality review (PQR) is a natural progression of GMP quality system 
implementation by manufacturers. This requirement was not new in the pharmaceutical industry 
before the PIC/S Guide, however the requirement started to be clearly specified after it. (37) 
 
Product Quality Review is therefore a regular periodic quality review of all licensed medicinal 
products which are conducted with the main objectives of highlight any overall trends (not 
necessarily visible with other quality systems) and to identify product / process improvements by 
verifying and identifying: 
- the consistency of the existing process(es); 
- trends in product data; 
- the appropriateness of current specifications for starting materials, intermediates and 
finished products; 
- the compliance of the registered particulars of pharmaceutical products (Marketing 
Authorisation); 
- deficiencies not detected by routine testing, monitoring or performance metrics; 
- opportunities for product and process improvements; 
- the need of change regulatory submisions. (38) 
Product Quality Review should typically be carried out for each product manufactured in the 
previous year. The review period can be extended beyond a year if duly justified (e.g. low batch 
numbers associated and low risk associated with the type of medicine). Such extensions shall be 
for a limited number of months and must be properly justified and described in the internal standard 
operating procedure concerning PQR´s. Implementation of preceding years’ recommendations 
shall also be reviewed and a risk-assessment approach (Quality Risk Management) must be used 
along the PQR. The PQR must be performed on a group of products with a particular characteristic. 
The products included in a group must be sufficiently similar, so that the parameters to be revised 
are representative of that group (eg. be of the same pharmaceutical form containing the same or 
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very similar active ingredients and excipients, and manufactured using the same type of 
equipment). 
PIC/S Guide to GMP (Clause 1.4) requires the following parameters (at minimum) to be assessed 
when conducting PQR: 
- Starting materials: a review of starting materials including packaging materials used in the 
product, especially those from new sources (e.g. batch, manufacturer, supplier, results of 
analytical tests); 
- In-process controls and quality control testing: a review of critical in-process controls and 
finished product results (e.g. trend in-process test results and Quality Control test results 
and yield reconciliation from stages); 
- Manufactured batches (intermediates, bulk, finished products and campaign batches): a 
review of all batches that failed to meet established specification(s) and their investigation; 
- Deviations and CAPA: a review of all significant deviations or non-conformances, their 
related investigations, and the effectiveness of resultant corrective and preventive actions 
taken; 
- Process or testing changes: a review of all changes carried out to the processes, or 
analytical methods; 
- Marketing authorisations: a review of Marketing Authorisation variations submitted/granted/ 
refused, including those for third country (export only) dossiers; 
- Stability program: a review of the results of the stability monitoring program and any 
adverse trends; 
- Complaints and/or adverse events: a review of all quality-related complaints and the 
investigations performed at the time; 
- Recalls: a review of all quality-related recalls and the investigations performed at the time; 
- Review of past PQR responses: a review of adequacy of any other previous product 
process or equipment corrective actions; 
- Post-marketing commitments: for new Marketing Authorisations and variations to 
Marketing Authorisations or a review of post marketing commitments (if any); 
- Equipment qualification: the qualification status of relevant equipment and utilities product 
related (e.g. HVAC, water, compressed gases, etc.) 
- Contractual agreements: a review of any contractual arrangements to ensure that they are 
up to date. (37) (38) 
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The collected data should be trended and analyzed to determine if the process is under control, if is 
capable and to assure the maintenance of validated status. Through trending can be 
established/revised in-process controls and can also be determined the appropriateness of current 
specifications both for starting materials and finished product. In addition, it is important to highlight 
any trends observed and to identify product and process improvements. Improvement plans and 
actions should be initiated and taken if the process is found to be out of control or has low 
capability indices.  
 
Working experience 
At Bluepharma PQRs preparation is responsibility of Product Quality & Compliance team 
(previously Quality Assurance team). PQ&C is responsible for collecting all relevant data, 
documents and information, however, summaries of results, recommendations, corrective actions 
and conclusions reflecting the data, evaluations and results authorisations, can be provided by 
other departments.  
PQ&C is responsible for assuring that all provisions of the internal respective Standard Operating 
Procedures are fulfilled, for coordinating the collection of data and information required, solicit all 
the PQR approvals and coordinate and assemble all corrective actions. The PQR´s are revised by 
Product Quality & Compliance members and are approved by Product Quality & Compliance 
Manager/ Qualified Person or her delegate. The final PQR´s are available for consultation in the 
intranet to all Bluepharma´s departments. Bluepharma´s PQRs are divided in twelve sections, 
according with related guidelines: 
- Raw materials/packaging materials: summary of the data concerning all raw materials/ 
packaging materials used in the production /packaging of the product under review will be 
done. It includes code number, supplier, manufacturer and batch numbers used. In the 
annex the relevant analytical data of the Drug Substance is shown and the results obtained 
for the Assay analyses are graphed in order to easily recognize the variations of this 
parameter between batches.  
- Critical in-process control and Quality control results: results from the in process controls, 
performed by production during the process, are shown in tables as well as all critical 
parameters in its production. The sets of In-process controls results are graphed in order to 
easily recognize the behavior of the batches throughout the processes considered. The 
tables and graphics used on the bulk review vary according with the pharmaceutical form 
(tablets, Certificate of Analysisted tablets and capsules) and critical parameters evaluated 
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(individual weight, thickness, hardness, length/diameter, disintegration, friability, average 
weight and weight of 10 tablets, disintegration, closure/visual aspect). Whenever possible 
limits/reference values of these parameters are mentioned. The partial and final yields of 
process are also indicated and analysed. Also, whenever is possible, the data of the critical 
analytical parameters (assay, dissolution and impurities) is graphed in order to easily 
recognize the variations between batches and evaluate the compliance with the 
specifications. 
- Batches failures and reworking/ repacking: the number of batches released and failed is 
presented and in case of batch failure, the reason to this event is stated as well as a 
summary of the performed actions. Also all repacked or reworked batches are mentioned, 
if any. 
- Deviations, non-conformities, Out of Specifications and Out of Trends: description of all 
significant deviations, non-conformities, Out of Specification and Out of Trends during 
production, packaging and analysis, their related investigations, follow-up and conclusions. 
If applicable, corrective or preventive measures are indicated. If possible, the 
manufacture/packaging deviations reported are represented graphically in order to identify 
recurrent problems and subsequently allowing the proposal of actions for its reduction. 
- Changes to processes, analytical methods, equipment and related documents: include an 
overview of all changes to processes, analytical methods and documents associated 
(manufacturing and packaging protocols, analytical protocols and specifications and 
approved models), used or not, concerning the product under review. 
- Marketing authorisation variations submitted during the review period: this is Marketing 
Authorisation Holders (MAH) responsibility. As contract manufacturers this point is not 
detailed in Bluepharma´s PQR. 
- Stability studies: The responsibility of this point is from MAH but Bluepharma as a 
manufacturer performs stability tests. The results are normally presented separately in a 
Stability Report. In this PQR section a review of the stability results and adverse trend 
analysis is presented. It is also stated if the results have been compliant with what is 
specified and if the expiration date defined is in accordance with the stability results 
collected during the period under review.  
- Returns, Complaints and Recalls: if any, every batch recalled, withdrawn from the market 
or any regulatory alert during the period under review must be listed on the PQR along with 
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the reason for the withdrawal or recall. Technical complaints received during the period 
under review are also listed and its evaluation and conclusions are also presented.  
- CAPA´s assessment and effectiveness: include a review of all deviations and other 
occurrences reported during the period under review that lead to CAPA, as well as an 
evaluation of the impact and effectiveness of previous year implemented CAPA´s, if any. 
- Post Marketing commitments: this section is intended to confirm if any post marketing 
commitments has been fulfilled but this is a MAH responsibility, therefore is not detailed in 
Bluepharma´s PQRs. 
- Qualification status of relevant equipment and utilities: this section is intended to present a 
summary of the qualification status of Manufacturing/Packaging equipment used 
concerning the product under review as well as other relevant equipment (heating, 
ventilating, and air conditioning, compressed air and purified water systems). Any deviation 
to the Annual Validation Master Plan must be indicated in this section.  
- Quality Agreement: This section should summarize the terms of the Technical Agreements 
established between contract giver and the contract acceptor that refer to bulk/finished 
products. Those contracts should assure that the manufacturing, packaging and/or testing 
is in accordance with the GMP guidelines and other legal requirements, including 
marketing authorisation. In this section it will be confirmed if all activities and 
responsibilities written are being fulfilled and if the Technical Agreement is up to date. 
Quality Agreements established with suppliers of drug substances and critical excipients, 
should also be checked for compliance and updated information. This data shall be 
provided by Quality Management department to the person in charge for the PQR. 
To fill in the sections described above, all documents which directly or indirectly refer to the 
manufacture, control or monitoring of a preparation in the period concerned must be analyzed. 
These include:  
- Manufacturing and packaging batch records and deviation reports (if any) 
- Raw materials/ packaging materials data (batch, manufacturer, supplier) 
- Specifications and Analytical Procedures (raw materials/ packaging materials/ bulk/ finished 
product) 
- Certificates of analysis (raw materials/ bulk/ finished product), Out of Specification reports 
and Out of Trends (if any) 
- Stability data and Out of Specification reports (if any) 
- Status of qualification/ validation of equipment and utilities 
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- Marketing Authorisations submitted, approved or rejected 
- Quality deviations  
- Complaints and Recalls 
- Quality Agreements 
While preparing PQRs I had the opportunity to know in detail all these documents and make a 
critical analysis over it and thus acquire a more comprehensive knowledge of the product, since the 
entry of raw materials, through product release, to customer satisfaction.  
I also had had the opportunity of update the internal Standard Operating Procedures of PQRs, 
according to recent updates of relative Guidances and with some related observations of clients 
during audits. 
 
 
2.1.2. Analytical Documentation 
 
Overall requirements 
Through its shelf life period a medicine product must conform to certain limits. To ensure 
compliance in practice is essential not only to have robust and in control manufacture processes, 
but also to have traceable quality control measurements systems. Storage conditions must also be 
under control.  
According to 21CFR211.160 (PART 211 -- CURRENT GOOD MANUFACTURING PRACTICE 
FOR FINISHED PHARMACEUTICALS Subpart I--Laboratory Controls) “laboratory controls shall 
include the establishment of scientifically sound and appropriate specifications, standards, 
sampling plans, and test procedures designed to assure that components, drug product containers, 
closures, in-process materials, labeling, and drug products conform to appropriate standards of 
identity, strength, quality, and purity.” (39) 
To set the quality level of the medicinal product for marketing, specifications, i.e. qualitative and 
quantitative parameters, related test procedures and acceptance criteria are stablished in the 
dossier for a marketing authorisation. The medicinal product must comply with this data at release 
and along its intended shelf life. (40) 
Chemical, Pharmaceutical and Biological documentation is provided by Module 3 of the CTD 
whose structure is detailed on the following figure 3.  
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Figure 3. – CTD Module 3 structure (41) 
 
For the purpose of this thesis only sections Control of the Drug Substance (3.2.S.4), Control of 
Excipients (3.2.P.4), Control of Drug Product (3.2.P.5), and Stability of Drug Product (3.2.P.8)  will 
be further detailed. 
 
Control of the Drug Substance 
The documents relating to the active substance present in module 3 includes the information 
provided by the manufacturer, through a European Drug Master File currently renamed as Active 
Substance Master File (EDMF/ASMF ) or a Certificate of Suitability to the Monographs of the 
European Pharmacopeia (CEP). The EDMF/ASMF is a document prepared by a Drug Substance 
manufacturer and submitted solely at its discretion to the appropriate regulatory authority in the 
intended drug market. The document provides the regulatory authority with confidential, detailed 
information about facilities, processes, or articles used in the manufacturing, processing, 
packaging, and storing of one or more human drugs. The EDMF/ASMF filing allows a firm to 
protect its intellectual property from their partners while complying with regulatory requirements for 
disclosure of processing details. The EDMF/ASMF is subdivided into two parts: Applicant's Part 
(also referred to as "Open Part") and a Restricted Part (also referred to as "Closed Part"). Only the 
Applicant's Part is available to the pharmaceutical entity that submits the application. The restricted 
part is available directly to the Competent Authority not being available for accessibility for the 
marketing authorisation holder. The CEP is a certificate granted by the Certification Secretariat of 
the EDQM that provide proof that a(n) (active) substance, manufactured in a specific site in 
accordance with the production process submitted by the manufacturer, can be properly tested and 
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inspected for quality, with monographic tests. Unlike the EDMF/ASMF, a CEP can be requested 
not only for any type of active substance but also for excipients. The CEP is optional and not a 
mandatory requirement in Europe for marketing substances. Nevertheless, it is the preferred option 
since authorities will generally accept this as proper proof of the active substance quality in 
marketing authorisation proceedings since it is issued as a result of an inspection performed by 
EDQM to the manufacture specific site. (42) 
The CTD sections concerning the drug substance (3.2.S) may be repeated if the product contains 
more than one active substance. (43) 
 
Control of Excipients 
Excipients are the constituents of a pharmaceutical form apart from the active substance. Include 
for e.g. fillers, disintegrants, lubricants, colouring matters, antioxidants, preservatives, adjuvants, 
stabilisers, thickeners, emulsifiers, solubilisers, permeation enhancers, flavouring and aromatic 
substances etc., as well as the constituents of the outer covering of the medicinal products, e.g. 
gelatine capsules. (44) 
The Control of Excipients is described in the 3.2.P.4 section and includes specifications (3.2.P.4.1) 
and, where appropriate, includes also the analytical procedures used for testing the excipients 
(3.2.P.4.2) and the justification for the proposed excipient specifications (3.2.P.4.4). 
The excipient used in a given formulation may be: 
-  described in monographs of the European Pharmacopoeia (Ph.Eur. or EP) or in the 
pharmacopoeia of an EU Member State; 
-  described in monographs of third country pharmacopoeias (e.g. United States 
Pharmacopoeia/National Formulary - USP/NF and Japanese Pharmacopoeia ); or, 
-  not described in any pharmacopoeia. 
When described in the EP or in the pharmacopoeia of an EU Member State a reference to the 
“current edition" of the pharmacopoeia should be included in the dossier. If tests other than those 
mentioned in the pharmacopoeia are used, proof should be supplied that the test methods are at 
least equivalent to those described in the pharmacopoeia. It may be necessary to add tests and 
acceptance criteria to the pharmacopoeial specification, depending on the intended use of the 
excipient (functionality-related characteristics). Where an excipient is neither described in the 
European Pharmacopoeia nor in the pharmacopoeia of a Member State, compliance with the 
monograph of a third country pharmacopoeia can be accepted provided that the applicant justify 
the reference to such pharmacopoeia and submit justified specifications in accordance with the 
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general monograph of the European Pharmacopoeia. For excipients not described in any 
pharmacopoeia an appropriate specification for the excipient should be established; this 
specification must be based on physical characteristics, identification tests, purity tests (including 
limits for total and individual impurities), assay or limit tests if necessary and corresponding 
validation parameters, and other relevant tests (e.g. on quantitative parameters which have 
demonstrated to influence the performance of the dosage form. (44) 
Justification of a specification takes into account the choice and particular use of the excipient. For 
excipients described in the European Pharmacopoeia, or in the pharmacopoeia of an EU Member 
State, justification of specifications will normally not be required. However, any particular 
acceptance criteria concerning the characteristics, as defined in Section 3.2.P.2.1.2, should be 
justified (e.g. particle size testing of a micronised substance). In addition, justification of a 
specification is not systematically required for well-known excipients (e.g. excipients which have 
been used in similar medicinal products for a long period of time). Where critical, the justification of 
specifications should provide information on excipient characteristics relevant to the medicinal 
product performance (Functionality related characteristics). (44) 
In general it is not necessary to carry out identity testing and an assay of the excipients in the 
medicinal product at release (except for situations envisaged in the Note for Guidance on 
Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug 
Products: Chemical Substances (CPMP/ICH/367/96)). Since the maintenance of the physico-
chemical properties of the medicinal product is partly dependent upon the properties and the 
stability of the excipients it should be ensured that antimicrobial preservative and, if appropriate, 
antioxidant levels are quantified periodically throughout the shelf-life according to  
current CHMP/ICH stability guidelines. (44) 
 
Control of Drug Product 
The information included in Module 3 for the finished product (3.2.P), refer to the qualitative and 
quantitative composition, manufacturing process, quality tests performed, information about 
containers and stability data to support the proposed shelf life. (17)  
The information on quality tests comprise specification(s) of the finished product (3.2.P.5.1), 
analytical procedures used for testing the drug product (3.2.P.5.2), the validation of Analytical 
Procedures (3.2.P.5.3) including experimental data for the analytical procedures used for testing 
the drug product, a description of batches and results of validation batch analyses (3.2.P.5.4), 
characterisation of impurities (3.2.P.5.5) if not previously provided in "3.2.S.3.2 Impurities", a 
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justification for the proposed drug product specification(s) (3.2.P.5.6) and reference standards or 
materials used for testing of the drug (3.2.P.6) if not previously provided in "3.2.S.5 Reference 
Standards or Materials".  
The analytical methods described in the various sections must have a level of detail such as that 
enables its reproduction by official laboratories. All tests must be validated in accordance with “ICH 
QA(R2) - Validation of analytical procedures” and the validation results should be made available. 
(43) 
Specification are defined in the ICH Q6 as a “list of tests, references to analytical procedures, and 
appropriate acceptance criteria, which are numerical limits, ranges, or other criteria for the tests 
described. It establishes the set of criteria to which a drug substance or drug product should 
conform to be considered acceptable for its intended use". Specifications are, therefore, one part of 
a total control strategy designed to ensure product quality and consistency. Conformance to 
specifications means that a specific material, when tested according to the detailed analytical 
procedures, will meet the listed acceptance criteria. Specifications are critical quality standards, 
proposed and justified by the manufacturer and approved by regulatory authorities. Since 
specifications are meant to confirm quality its content is focused on those characteristics found to 
be useful in ensuring the safety and efficacy of the drug product, rather than to establish full 
characterization. (45) 
In order to determine the specifications of the finished product, parameters related to the 
manufacturing process should be taken into account. An appropriate specification for the 
parameters studied during the phase of development and during the validation of the 
manufacturing process should be determined. At least those aspects considered to be critical 
should be the object of specifications routinely verified. (40) 
The description of the dosage form, the identification of the drug substance(s) in the drug product, 
the assay of the drug substance(s) in the drug product and impurities (including degradation 
products addressed in the “Q3B(R2) - Impurities In New Drug Products” and residual solvents) are 
considered generally applicable to all drug products. In addition to these tests, other may be 
considered on a case by case basis for drug products, for e.g. for tablets and hard capsules it can 
be included the dissolution, disintegration, uniformity of dosage units, water content and microbial 
limit tests. (45) 
Periodic or skip testing may be applicable to some tests as, for example, residual solvents and 
microbiological testing for solid oral dosage forms. This consists on the “performance of specified 
tests at release on pre-selected batches and / or at predetermined intervals, rather than on a batch-
to-batch basis with the understanding that those batches not being tested still must meet all 
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acceptance criteria established for that product”. Since this represents a less than full schedule of 
testing it should be justified, presented to and approved by the regulatory authority prior to 
implementation. This concept should generally be implemented post-approval since there is limited 
data available at the time of submission of an application. (40) (45) 
Different acceptance criteria for release and shelf-life specifications can be applied to drug 
products. The applicant proposes a shelf life for the medicinal product mainly on the basis of the 
level of active constituents (efficacy) and the admissible level of any breakdown products or 
impurities (safety) and consistent pharmacotechnical properties. From the behaviour of the 
medicinal product the applicant deduces the appropriate storage conditions which will maintain 
compliance with the specifications of the medicinal product. The specification limits of the finished 
product at the time of batch release are set by the marketing authorisation applicant such that the 
specifications proposed for shelf life are guaranteed and are established on the basis of a critical 
detailed review of the data gathered from the batches analyzed. However, specifications of the 
finished product at manufacture may be different from those of the medicinal product at shelf-life 
due to the fact that, in certain cases, some characteristics of the medicinal product (e.g. assay and 
impurities) may change during storage under the approved conditions, like impurities and 
pharmacotechnical properties; therefore, the quality required at the end of shelf life should be taken 
into account in determining appropriate specifications at the time of manufacture. In Japan and the 
US, this concept may only be applicable to in-house criteria, and not to the regulatory release 
criteria. Thus, in these regions, the regulatory acceptance criteria are the same from release 
throughout shelf-life; however, an applicant may choose to have tighter in-house limits at the time 
of release to provide increased assurance to the applicant that the product will remain within the 
regulatory acceptance criterion throughout its shelf-life. In the European Union there is a regulatory 
requirement for distinct specifications for release and for shelf-life where different. (40) (45)  
 
Stability of Drug Product  
Stability testing is performed to provide evidence on how the behavior of a drug substance or drug 
product varies over time under the influence of environmental factors such as temperature, 
humidity, and light. It is also important to establish a re-test period for the drug substance or a shelf 
life for the drug product and recommended storage conditions. (46) 
ICH Q1A guideline is the ICH guideline where is defined the stability data package for a new drug 
substance or drug product sufficient for a registration application within the three regions of the EC, 
Japan, and the US. Tests conditions defined in this guideline are based on an analysis of the 
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effects of climatic conditions in these three regions and therefore this guideline do not necessarily 
cover testing for registration in or export to other areas of the world. Besides the world can be 
divided into four climatic zones, I-IV, based on climatic data, this guideline only addresses climatic 
zones I and II. It was established that stability information generated in any one of the three 
regions, EC, Japan and the US, would be mutually acceptable to the other two regions, provided 
that the information is consistent with ICH Q1A guideline and the labeling is concordant with 
national/regional requirements. (46) 
Two different types of stability studies can be performed along the medicine life-cycle: 
- real time stability studies  
- accelerated stability studies 
In real-time stability studies, a product is stored at recommended storage conditions and monitored 
until it fails the specification. In accelerated stability studies, a product is stored at elevated stress 
conditions (such as temperature, humidity, and pH). (46) 
In the development phase accelerated stability tests are performed in order to select adequate 
formulations (from the viewpoint of stability) and container-closure systems by comparing different 
alternatives. Once the final formulation and manufacturing process have been established, the drug 
product undergo a series of accelerated stability tests to predict its shelf-life and storage conditions. 
For confirmation purposes real-time studies must be started at the same time. Since the drug 
regulatory authority will require information on the stability of the final product, in the final container 
and packaging, at registration should be presented the data from both accelerated and real-time 
studies. With regulatory approval, is often established a provisional shelf-life period, provided that 
the owner of the dossier commits itself and signs a declaration stating that the necessary studies 
will be continued and completed and that the respective results will be submitted to the registration 
authority. In the post-registration period, real-time stability studies must be carried on by the 
manufacturer to substantiate the expiry date and the storage conditions previously proposed and 
all the data obtained must be submitted to the registration body. Other results of on-going stability 
studies can be verified in the course of GMP inspections. National health authorities should also 
monitor the stability and quality of preparations on the market, through a follow-up inspection and 
testing programme, to ensure its quality and safety of products. Whenever major modifications are 
made to the formulation, manufacturing process, packaging or method of preparation additional 
stability studies are required and the results of these studies must be communicated to the 
competent drug regulatory authorities. (47) 
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Given all the previous assumptions, the section of Stability Data of Module 3 must include: a 
stability summary and conclusion sub-section (3.2.P.8.1), where are summarized the types of 
studies conducted, protocols used, results of the studies and conclusions with respect to storage 
conditions and shelf-life, and, if applicable, in-use storage conditions and shelf-life; a post-approval 
stability protocol and stability commitment (3.2.P.8.2); a stability data sub-section (3.2.P.8.) where 
should be presented, in an appropriate format (e.g. tabular, graphical, narrative), stability studies, 
information on the analytical procedures used to generate the data and validation of these 
procedures; finally information on characterization of impurities is included in the sub-section 
3.2.P.5.5. (43) 
 
 
Working experience 
PQ&C department has the responsibility of preparing/revising Analytical Documentation concerning 
products that already have a marketing authorisation. This includes specifications of excipients, 
drug substances, packaging materials, bulk product and finished product, and related analytical 
protocols. 
The preparation of analytical documentation of raw materials or packaging materials used in the 
R&D projects is also PQ&C´s responsibility. 
My function concerning analytical documentation has been focused in the preparation and review 
of specification of excipients, drug substances and bulk product and their related analytical 
protocols, when applicable. 
Internal Specifications serve as base for Quality Control analysis of tests results and approval of 
batches and therefore must be updated as well as the internal related protocols, when existent. 
Excipients specifications may be divided in specifications based on official monographs and 
specifications based on the manufacturer's documentation. Monograph specifications correspond 
to the majority of the specifications of excipients. May be based in official monographs of the 
European Pharmacopoeia (Ph.Eur.), in the American Pharmacopoeia (USP/ NF) or based on both, 
according to the market to which is intended the final product. For these specifications there is no 
need to prepare a related analytical protocol since the analytical methods to be used are described 
in its correspondent monograph. Periodically are published and implemented new volumes or 
supplements of the EP and the USP/NF. Therefore, all Bluepharma´s excipients specifications 
based on monographs are reviewed periodically, to check if the new editions/supplements 
introduce any changes on it; a new edition of the document is issued internally on every review. 
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The new volumes and supplements are published a few months before the date of its 
implementation allowing an early evaluation of impact and the implementation of internal updated 
specifications at the edition or supplement´s implementation date. In order to easier this task, for 
each edition / supplement of Ph.Eur. and of USP/NF, are published in advance lists with texts, 
chapters and monograps revised, corrected or new (Contents of Supplement for the Ph.Eur. and 
Admissions and Annotated Lists for the USP/NF). Some of the changes described on these lists 
are to be take into account at the publication date of the volume/ supplement (eg the "corrected 
Texts" of Ph.Eur.). For raw materials that don´t have a correspondent monograph neither in the 
Ph.Eur. or in the USP, is prepared a specification and a related analytical protocol based on the 
information provided by the manufacturer (Technical Data Sheet).  
As it is for excipients, Drug Substances (DS) can have an official pharmacopoeia monograph 
associated or not. When there is an official monograph published, the manufacture of that DS can 
apply for a CEP. If the manufacturer demonstrate that their product complies with the quality 
standards required by the Ph. Eur. and European regulations, is suitability to be controlled 
according to the Ph. Eur., complies with the relevant GMPs (GMP) and if the manufacturer accept 
a site inspection at any time at the request of the EDQM, this entity issue a CEP. This certificate 
can be included in the CTD application easing the DS use approval by the competent authorities 
since it constitutes a proof of its quality.  
The specifications and related analytical protocols used to control a given DS at receipt in 
Bluepharma must be, in any case, compliant with the content presented in the 3.2.S.4.1 and in the 
3.2.S.4.2 of the CTD, respectively, or on equivalent sections of the ANDA. When a CEP is included 
in the section 3.2.S.4.1 there is no need to elaborate a related analytical procedure, provided that is 
made a reference in the internal specification to the monograph that should be followed and are 
included additional tests described in the CEP (e.g. residual solvents and impurities), in annex. For 
DS that doesn´t have a CEP a specification and a related analytical procedure is prepared, based 
on the correspondent DMF.  
Both for excipients and DS, testing should be performed for residual solvents when production or 
purification processes of those raw materials are known to result in the presence of such solvents 
(listed in the ICH Q3C(R5) - Impurities: Guideline for Residual Solvents). That information must be 
provided to Bluepharma by the manufacturer of the excipient/DS (technical documentation, 
Certificate of Analysis) so that the limits and methods may be included in the related 
documentation of that raw material (residual solvents analytical methods are included as annexes 
for specifications based on monographs). 
University of Aveiro 2014 Masters in Pharmaceutical Biomedicine 
 
42 
 
Bulk specification and analytical procedures must also be necessarily in compliance with the 
related sections of the CTD (3.2.P.5 for release and 3.2.P.8 for stability) or the ANDA. 
Specifications of products meant for Europe are prepared including both release and stability limits, 
since these may differ as mentioned above.  
To each bulk product corresponds an analytical procedure where are described the approved 
methods contained also in CTD (3.2.P.5.) or equivalent section of ANDA. Methods must be 
validated in Bluepharma´s Laboratories according to the “ICH QA(R2).  
The task of PQ&C regarding analytical documentation is not only limited to the preparation of 
specifications and associated analytical procedures. Is also performed a thorough job of checking 
the compliance of these documents with the constant updates that are made in the documents 
used as their basis. In the case of drug substances and bulk specifications, every time that it is 
submitted and approved by the authorities an amendment to CTD concerning the respective 
modules of CTD (3.2.S.4.1 and in the 3.2.S.4.2 for drug substance and 3.2.P.5 and in the 3.2.P.8) 
or the equivalent sections of ANDA, an internal update of the specifications and analytical 
procedures concerned must be performed accordingly.  
Additionally some clients routinely contact the department of PQ&C and request a document 
signed confirming that our internal documentation is updated, according with the last version 
approved of the related sections of the dossier. 
All the changes performed in our internal documentation must be supported by a Change Control 
Report, where must be described the change performed, the reason, its impact, the Risks related 
with that change and a detailed related Action Plan.  
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2.2. Additional Activities Performed 
Additionally to the main tasks described before, I have been giving support to other tasks 
developed in the PQ&C department. Of the several tasks performed I highlight the support given in 
the first months to the Qualified Person (QP) on reviewing the compliance of batch related 
documentation for emission of the Certificate of Compliance (Certificate of Compliance) for Batch 
Release, the constants support on Audits/Inspections, the attended training and the training given 
to new employees or colleagues who assumed tasks on which I have confirmed experience. 
 
2.2.1. Support to the QP Batch Release  
 
Overall requirements 
All batches of medicines for human use (MHU), medicines for veterinary use (MVU) and 
experimental medicines must be certified by a Qualified Person or in the case of the US market, 
the by the Quality Unit, before being approved for sale / supply or for trials in the case of 
experimental drugs. This certification is designed to ensure that the batch was manufactured, 
packaged and analysed in accordance with the requirements of the Marketing Authorisation 
Dossier (MAD) or Abbreviated New Drug Application (ANDA) / New Drug Aplication (NDA) 
(regulatory compliance), Dossier Project (Product Specification File) Regulatory Documentation 
approved Good Manufacturing Practices and other applicable legislation. 
The verification of all packaging and manufacturing documentation is a responsibility of the 
respective sectors (sectors responsible or his delegate) but a final assessment is conducted by the 
Qualified Person (QP) or its delegate in Product Quality & Compliance. Verification of analytical 
documentation (including calculations) and respective internal approval is the responsibility of the 
Head of Quality control and the entire procedure is described in an internal Standard Operating 
Procedure. 
After that a compilation of documents concerning the production and / or packaging and analytical 
control of a product batch must be performed and in Bluepharma this is a responsibility of the 
QP/PQ&C department. This batch documentation includes: 
- Manufacturing documentation: manufacturing batch record and, if applicable, deviation 
reports; 
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- Certificate of analysis (Certificate of Analysis) of batches of active substance and, if 
applicable, Out of Specification reports; 
- Certificate of Analysis of bulk product and, if applicable, Out of Specification reports; 
- Packing documentation: packing record) and Out of Specification reports, if applicable; 
- Certificate of Analysis of finished product and, if applicable, Out of Specification reports; 
- In the case of a product destined to the US, are also included certificates of the analysis, of 
all raw materials contained in the formulation, for confirmation / verification of its analysis 
under the USP pharmacopoeia. 
For each batch all these documents are verified taking into account the data of submission and 
approval by the authorities (MAD, regulatory documents approved), GMPs and other legislation in 
force (Compliance). The compliance of the batch is verified and a Certificate of Compliance and 
Release is issued. The final release of the product is done in the computerized system SAP, by the 
QP, not being possible to ship the product without this action.  
At the same time is sent to the client documentation concerning the approval/ release of the 
product in accordance with what is defined in the Quality Agreement between Bluepharma and the 
client. 
For internal management, once this process is completed is filled a table with product data, 
including: product type certificate (Bulk, Finished Product), product name according to SAP 
(including name, strength, pharmaceutical form and presentation), batch number; quantity, 
observations (if is a quarantined shipment, if is launch, among others); date of shipping/ 
certification, direct client´s name followed by the name of the final client. 
In Bluepharma the archive of all batch related documentation of medicinal products for human use 
and investigational medicinal products is a responsibility of the Product Quality & Compliance 
Department. Batch documentation MHU / MVU should be kept for one year after the expiry of the 
product in a minimum at least of five years after certification by the Qualified Person, or in 
accordance with the Quality Agreement signed between Bluepharma and the client. For 
experimental medicines, the batch documentation should be maintained for at least five years after 
completion or formal discontinuation of the last clinical trial in which the batch was used. 
 
Working experience 
At the time I began my professional experience in Bluepharma, due to a sharp increase in 
production given a global launch of a new generic, there was a requirement to assist in the task of 
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support to QP for batch release. I had performed this task for four months, till the admission of new 
collaborators. Thus this was my first concrete task performed in Bluepharma.  
My function was to compile and select all the batch documentation from manufacturing, packaging 
and quality control departments (product documentation), prepare the Certificate of Compliance 
and send the approved and selected documents for the client. The Certificate of Compliance is 
signed by the QP after the verification of compliance of all product documentation that includes: 
manufacture records, packaging records, quality control records and deviation reports (if any). The 
documents that support and that must be sent attached with the Certificate of Compliance are 
compiled according to what is defined in the client´s respective Quality Agreement.  
Along with the e-mailing of Certificate of Compliance and associated documentation I was also 
responsible for sending, when applicable, samples of the product to clients, via a specialized 
courier company. I also had the responsibility of updating the table where is registered de data of 
every batch release, archive all the related documents (digital archive in Bluepharma´s intranet) 
and archive the paper documents batch related. 
 
 
2.2.2. Audits/ Inspections  
 
Overall requirements 
Auditing is a critical function within a pharmaceutical company since this industry in highly 
regulated. Audits provide information to the Authorities and/or Clients about how effectively the 
company controls the quality of their processes and products. Therefore is essential the 
anticipation and verification of all matters that may be raised by the audit authority to ensure 
greater responsiveness and assertiveness and thus gain the confidence of those entities. Facility 
audits/inspections can be focused on several points, including: 
 Review of facilities for GMP compliance with EMA/FDA regulations and guidelines, 
International Conference Harmonization (ICH) Guidances and client specifications 
 Review all pertinent documents that support GMP and client specifications 
 Inspect facilities, equipment, and laboratories 
 Assess Quality Systems including all internal Standard Operating Procedures and 
associated GMP documents 
 Assess CAPA programs (Corrective Action/ Preventive Action) 
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 Review validation of manufacturing equipment, product process, and equipment cleaning 
 Assess Vendor Certification Programs 
 Review method validation (analytical and microbiological) 
 Evaluate data integrity 
 Assess qualification and training of personnel 
 Assess supplier qualification 
 Review Change Control Records, Complaints, Deviations and Out of Specifications. 
Audits are followed by the Head of Quality Departments and is crucial the support of their team in 
the success of the Audit.  
 
 
Working experience 
Bluepharma is a GMP certificated company by INFARMED, I.P and is authorised by the same 
entity to manufacture different non-sterile products in the following solid dosage forms: capsules, 
hard shell, tablets, powder and granules. The INFARMED´s Inspection Unit performs regular 
supervision and inspection activities in Bluepharma´s facilities to check the implementation of best 
practice systems in accordance with national and international standards established procedures 
by the European Commission in different areas of intervention by the European Medicines Agency 
(EMA) and the System International Cooperation of the Pharmaceutical Inspectorate Services (PIC 
/ S).  
FDA inspects foreign manufacturing sites for FDA-regulated products that are sold in the United 
States. FDA conducts several types of inspections to help protect consumers from unsafe 
products: pre-approval inspection after a company submits an application to FDA to market a new 
product; routine inspection of a regulated facility (performed every two years) and “for-cause” 
inspection to investigate a specific problem that has come to FDA’s attention. In 2009 Bluepharma 
was inspected by the FDA for the first time and obtains official approval for the development / 
manufacture of solid pharmaceutical forms to be exported to the US market. After that, two more 
inspections (routine inspections) were performed in Bluepharma facilities. 
Bluepharma's main business aims at the integration of the licensing of its in-house developments 
coupled with the supply of the finished product. Bluepharma collaborates with the major European 
generic pharmaceutical companies, while distributing medicines worldwide, having a wide range of 
clients. Being Bluepharma a contract manufacturer and a developer and contract research 
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company of medicinal products, clients and potential clients audits are a constant. Their 
satisfaction during the audits is essential for the maintenance of the business already established 
and to achieve new business opportunities and thus contribute to the company's success.  
During my professional experience at Bluepharma I had the opportunity of helping on the 
preparation and giving support to two Infarmed Inspections and two FDA Inspections and several 
clients or potential clients audits. I had also the opportunity of performing tasks defined in action 
plans resultant from questions that arose during the course of inspections / audits. 
 
 
2.2.3. Trainning 
 
Overall requirements 
Employee is the valuable resource for any organization. The success and failure of an organization 
extremely depends on the performance and productivity of employees. Training enables people to 
acquire new skills, to enhance their skills and keep them updated with recent changes and 
therefore has a significant role on productivity, its boosting its increase.  
 
Working experience 
Given the various restructurings that were made in the department in which I work, either with the 
division of quality assurance, or with changes in human resources, it was necessary to readjust 
tasks and thus have / give training. Giving these adjustments I had the opportunity to train 
colleagues on tasks for which I was able (previously described as main). I also had the opportunity 
to give a brief training on these tasks to new employees in order to make them know the work 
performed in the PQ&C department.   
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2.3. On-the-job additional learning 
Bluepharma is a certified company and consequently the integration of new collaborators comply 
with certain requirements, in particular training/information sessions concerning the main rules and 
principles of different areas of the company. Therefore, in the first days at Bluepharma, in order to 
acquire knowledge in general areas that were transversal to all company departments, I had to 
read the company’s Site Master File and also relevant Standard Operating Procedures for my 
future functions. I also had to attend training sessions concerning general issues applicable to the 
entire company. From these I highlight the following:  
- “Welcome” manual 
- Bluepharma Quality Management System  
- Environment and Safety Management System 
- GMPs 
- Innovation and R&D certification 
- Information technology services  
Throughout last year’s Bluepharma gave me also the opportunity of attending different types of 
training sessions. Some of them were general and mandatory for all collaborators; others were 
specific and intended to provide knowledge in specific issues related with new tasks to perform. 
From the last ones I highlight, among others, the sessions on GMP continuous learning, sessions 
concerning CTD contents and regulatory requirements, Out of Specification / Out of Trend, new 
legal requirements on active substances, deviation reports management and change control 
management regarding documentation. 
Those training sessions were very useful to refresh some concepts learned in my academic 
journey as well as to acquire new concepts, such as GMP, Quality systems and national and 
international regulations and guidelines. 
I have also attended some additional brief formative sessions (previously named “paper clubs” and 
now “Forum of Innovation and Quality”), which addressed different knowledge areas around the 
pharmaceutical industry and other internal seminars regarding relevant company related issues for 
workers clarification. 
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3. Discussion 
A work experience at a Quality Assurance/ Product Quality & Compliance department of a 
Pharmaceutical Industry provides the opportunity to perform several different activities and gain a 
more comprehensive understanding of the company, of the activities developed in the different 
departments and of the interactions established between them. 
At Bluepharma my working experience started to be focused on support to batch release, followed 
by Product Quality Reviews preparation and finally has been directed to the preparation and 
compliance verification of analytical documentation.  
Qualified Person is responsible for the release of the product to clients/ clinical trials. The product 
only can be released after a proper review of the batch documentation (production and packaging 
records and deviation reports, if any), and if the quality control testing data confirm that the product 
meets specifications. If there is some deviation that can affect the quality, safety and efficacy of the 
product, the batch must be rejected and an investigation must be performed to find the root cause 
of the problem occurred. The batch release is, therefore, an activity of great responsibility and the 
utmost importance for the company. On Quality Agreements are detailed several requirements 
concerning the documentation batch related that must accompany the Certificate of Compliance. 
This way, the support provided to the emission of the Certificate of Compliance is of great 
importance to ensure clients satisfaction and compliance with those requirements. While 
performing this task I was able to collect, compile and archive batch manufacturing, packaging and 
quality control documentation, compile the “Release Documentation” and deliver it to the client. 
This task was a very enriching experience, first of all due to the fact that, till then, I did not have 
previous experience in the Pharmaceutical Industry area; by performing it, I had the opportunity of 
become familiarized with the manufacturing, packaging and quality control documentation as well 
as become aware of the requirements that must be fulfilled in order to release a batch for the 
market. By accomplishing this task I realized that this is not always easy, since there are deadlines 
to release and ship the product to customers and the execution of PQ&C functions is dependent on 
the flow of documents between the different departments involved.  
PQRs are an effective quality improvement tool to enhance the consistency of the processes and 
the overall quality of the product since it provides a broader view of product data, and enables the 
capture of trends and help to determine the need for revalidation and changes, if needed. PQR´s 
can be considered as a continuous validation of the product during its life-cycle. The PQR´s task 
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comprise the collection of all manufacturing, packaging and quality control data, deviation and Out 
of Specification reports, stability data and Quality Agreements, the analysis of trends and 
processing of batch related data, the draft of the report itself; the delivery of it to the client and, if 
requested, the clarification of their doubts. While preparing PQRs I have been giving the 
opportunity to know in detail all the product related documents, to make a critical analysis over it 
and thus acquire a more comprehensive knowledge of the product and of all the processes needed 
to obtain it, since the entry of raw materials, passing through product release, to customer 
satisfaction. I consider the preparation of PQR´s a very challenging task, not only because it gives 
me a tremendous knowledge on the pharmaceutical industry reality but also for its enormous 
importance in assessing the quality of the product and promoting their continuous improvement 
and thus higher client’s satisfaction. 
Quality control is a procedure or set of procedures through which is ensured that all the materials, 
intermediate products and the finished products comply with a defined set of quality criteria or 
meets the requirements of the client (according to the Marketing Authorisation dossier). Since drug 
products must be marketed as safe and its performance must be consistent and predictable quality 
control is an essential operation of the pharmaceutical industry. Of great importance are also the 
documents used as a basis and guidance to these tasks undertaken in quality control department, 
such as the specifications and related analytical protocols. At Bluepharma the preparation, review 
and update of specifications and analytical protocols for excipients, drug substances and bulk 
product is QP&C responsibility as well as the assessment of compliance of that documentation. 
Given the huge amount of excipients and active substances used, the diversity of products that are 
produced and the variety of customers with different Marketing Authorisations, the preparation of 
analytical documentation and the verification of its compliance is undoubtedly a very challenging 
task and requires tremendous work and constantly updated to ensure compliance. This task is also 
quite rewarding once there is a permanent involvement of other departments, including the quality 
control, stability department and regulatory affairs, enabling me to acquire new knowledge every 
day. 
Auditing is a critical function within a pharmaceutical company since it provides information to the 
Authorities and/or Clients about how effectively the company controls the quality of their processes 
and products. Support tasks performed before and during inspections/ audits are therefore of 
extremely importance to ensure greater responsiveness and assertiveness and thus gain the 
confidence of the inspectors/auditors. This task was very enriching, not only because it confronts 
us with the huge level of requirements of the inspection and audit entities as well as it continuous 
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alert us to numerous points for improvement, even when the audited company is governed by high 
quality standards and complies with all its legal obligations, as in the case of Bluepharma. 
All these hard skills described above enabled me to deepen my knowledge about the structure and 
functioning of a Pharmaceutical company and continually update my knowledge on ISO standards, 
GMP's and other regulations with great impact on the company. Besides the tasks described 
above, I was also able to: 
- elaborate and review Standard Operating Procedures applicable to the PQ&C department 
or related with its functions; 
- perform all procedures related to the preparation, review, approval and document 
distribution; 
- reply to requests for clarification or doubts raised internally or by customers in relation to 
specific tasks performed or general questions related to Product Quality and Compliance; 
- provide training to colleagues and new collaborators. 
Training sessions were also very useful to refresh some concepts learned in my academic journey 
as well as to acquire new concepts, such as GMP, Quality systems and national and international 
regulations and guidelines.  
Along my professional experience at Bluepharma I have been giving also the opportunity of 
developing and improving some soft skills. Responsibility sense was definitely one of the soft skills 
more enhanced during this experience since the activities performed in the PQ&C department are 
of extreme importance and have a high impact on the company. All activities must be performed 
with high precision and accuracy. Thus I had to learn to be more careful in the execution of my 
duties, even in the simplest ones. The existence of deadlines and the development of different 
tasks determined the development of time management and organizational skills. I have learned to 
plan my work day in advance and organize my tasks according to their priority, and thus carry them 
all quickly and efficiently. I also have learned how to deal with unforeseen circumstances that force 
me to change my plan and reorganize my tasks in order to not jeopardize the deadlines. I also 
have developed my verbal and written skills, including in English. This learning is important not only 
to prepare documents but also to present and discuss ideas on an assertive way. I also have 
improved my self-assessment capacity, in order to understand why mistakes occur, what can be 
improved, and how; I have also developed my autonomy, my capacity of critical thinking and 
problem solving and my team work ability. 
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Some of these learnings were previously acquired throughout life and with my previous academic 
and professional experiences. However, this professional experience confronted me with new 
situations and allowed the development and improvement of all these skills. For that, was crucial 
the support of my work colleagues and the orientation of the person responsible for the QP&C 
department.  
Along my journey at Bluepharma I have also faced some difficulties, mainly due to several 
restructuring of the department over this period with consequent reorganization of tasks. Another 
difficulty identified in the performance of my duties is related with the communication between 
departments that sometimes tends to hinder the realization of the tasks on time. 
Therefore, this professional experience was not always a simple process, however it has been 
always a very challenging experience that made me a more versatile and flexible person and that 
continuously provide me the opportunity of acquire knowledge in different areas of the 
pharmaceutical industry.  
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4.  Conclusion 
This thesis intends to present the necessary steps for develop professional experience on Product 
Quality and Compliance in a Pharmaceutical Industry. In this case reflecting my personal 
experience, by describing the activities performed and the learnings and skills acquired, as well as 
highlight the importance of the work developed in this department and its contribute to the  good 
performance of the company and to the achievement of their objectives and mission. 
Working in this field gives to the professional the opportunity of gaining a broad understanding of 
the pharmaceutical industry, pharmaceutical quality systems and the drug development process. In 
my case it allowed me to refresh theoretical knowledge acquired during my degree in 
Pharmaceutical Sciences, as well as in my Master’s Degree in Pharmaceutical Biomedicine and 
also gave me the possibility to reflect on my weaknesses and strengths and of developing my 
capability to handle with stressful and challenging real life situations, forcing me to improve the less 
positive aspects every day.  
The activity of a Product Quality and Compliance department is transversal to the entire company 
involving constant communication with all company departments. QP&C department of 
Bluepharma is responsible for the preparation of the documents product related necessary for 
development and routine production as well as for the documents required to control and 
monitoring the majority of the processes, and therefore its role in the company is crucial to 
development of the activities of the company and the achievement of their objectives and quality 
standards of excellence.  
The tasks that I have been performing are just a small part of the entire work developed in this 
department but highlight its crucial role on maintaining and assure the quality standards required in 
the pharmaceutical industry. 
Working on Product Quality &Compliance provides every day the opportunity to influence working 
practices in order to improve standards of quality, that include the commitment to GMP and an 
integration of their requirements into the tasks for which I am responsible.  
The performance of my duties in the Product Quality &Compliance department has been a very 
enriching experience since I am constantly developing my knowledge and skills and I am 
confronted every day with new challenges. All these challenges that I underwent through enabled 
my professional and personal growth always towards a continuous improvement. 
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